

In the specification:

On page 1 after the title please insert the following:

C1 This application claims the benefit of U.S. Provisional Application No. 60/078,371 filed March 18, 1998. --

Please replace page 35, line 26 to page 36, line 1 with the following:

C2 -- Figure 7 shows the inhibition of the binding of biotinylated recombinant Bet v 1 (SEQ ID NO: 37) to serum IgE from a pool of allergic patients by non-biotinylated Bet v1 (SEQ ID NO: 37) and by Bet v1 Glu60Ser mutant (SEQ ID NO: 37). In contrast to the Glu45Ser, Pro108Gly and Asn28Thr+Lys32Gln mutants (SEQ ID NO: 37), the substitution glutamic acid 60 to serine, does not show any significant effect on the IgE- binding properties of Bet v 1 Glu60Ser mutant (SEQ ID NO: 37). This indicates that substitutions outside the defined *Fagales* common patches only have a marginal effect on the binding of specific serum IgE supporting the concept that conserved allergen molecular surface areas harbor dominant IgE-binding epitopes. --

In the Abstract:

Please replace the abstract with the following:

C3 -- Novel recombinant allergens are disclosed. The allergens are non-naturally occurring mutants derived from naturally-occurring allergens. The overall  $\alpha$ -carbon backbone tertiary structure of the allergens is essentially preserved. Also disclosed are methods for preparing the recombinant allergens as well as the use of the recombinant allergens for the treatment of allergic reactions. --

In the claims:

Please cancel claims 1, 15

- sol 2. (Twice Amended) A recombinant allergen according to claim 48, obtainable by  
a) identifying amino acid residues in a naturally occurring allergen which are conserved with more than 70% identity in all known of the homologous proteins within the taxonomic order from which said naturally occurring allergen originates;